Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist

Transfusion

Volumn 45, Issue 3, 2005, Pages 295-300

  Liles, W Conrad ^b   Rodger, Elin ^b   Broxmeyer, Hal E ^b   Dehner, Christine ^b   Badel, Karin ^b   Calandra, Gary ^b   Christensen, Jeff ^b   Wood, Brent ^b   Price, Thomas H ^b   Dale, David C ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); CD34 ANTIGEN; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ARTICLE; BLOOD CELL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN EXPERIMENT; IMMUNOCOMPETENT CELL; LEUKAPHERESIS; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; SINGLE DRUG DOSE; STEM CELL MOBILIZATION;

ANTI-HIV AGENTS; ANTIGENS, CD34; COHORT STUDIES; DRUG SYNERGISM; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HETEROCYCLIC COMPOUNDS; HUMAN EXPERIMENTATION; HUMANS;

EID: 20144362394     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2005.04222.x     Document Type: Article

References (38)

1. Schots R, Van Riet I, Damianos S, et al. The absolute number of circulating CD34+ cells predicts the number of hematopoietic stem cells that can be predicted by apheresis. Bone Marrow Transplant 1996;17:509-15.
2. Schwella N, Beyer J, Schwaner I, et al. Impact of preleukapheresis cell counts on collection results and correlation of progenitor cell dose with engraftment after high-dose chemotherapy in patients with germ-cell cancer. J Clin Oncol 1996;14:1114-21.
3. Korbling M, Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? Blood 2001;98:2900-8.
4. Lapidot T, Petit I. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol 2002;30:973-81.
5. Aiuti A, Webb IJ, Bleul C, Springer T, Gutierrez-Ramos JC. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med 1997;185:111-20.
6. Kim CH, Broxmeyer HE. In vitro behavior of hematopoietic progenitor cells under the influence of chemoattractants: stromal cell derived factor-1, Steel factor, and the bone marrow environment. Blood 1998;91:100-10.
7. Peled A, Petit I, Kollet O, et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 1999;283:845-8.
8. Hattori K, Heissig B, Tashiro K, et al. Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. Blood 2001;97:3354-60.
9. Mohle R, Bautz F, Rafii S, et al. The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood 1998;91:4523-30.
10. Kollet O, Petit I, Kahn J, et al. Human CD34(+) CXCR4(-) sorted cells harbor intracellular CXCR4, which can be functionally expressed and provide NOD/SCID repopulation. Blood 2002;100:2778-86.
11. Hatse S, Princen K, Bridger G, De Clercq E, Schols D. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett 2002;527:255-62.
12. Gerlach LO, Skerlj RT, Bridger GJ, Schwartz TW. Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor. J Biol Chem 2001;276:14153-60.
13. Liles WC, Broxmeyer HE, Rodger E, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003;102:2728-30.
14. Hendrix C, Collier AC, Lederman M, et al. AMD3100 CXCR4 receptor blocker fails to reduce HIV viral load by > 1 log following 10-day continuous infusion. Conference on Retroviruses and Opportunistic Infections; 2002 Feb; Seattle, WA; Abstract 391-T.
15. Keeney M, Chin-Yee I, Weir K, et al. Single platform flow cytometric absolute CD34+ cell counts based on the ISHAGE guidelines. Int Soc Hematother Graft Eng Cytometry 1998;34:286-8.
16. Hubel K, Liles WC, Broxmeyer HE, et al. Leukocytosis and mobilization of CD34+ hematopoietic progenitor cells by AMD3100, a CXCR4 antagonist. Supportive Cancer Ther 2004;1:165-72.
17. Levesque JP, Hendy J, Takamatsu Y, et al. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest 2003;111:187-96.
18. Rosu-Myles M, Gallacher L, Murdoch B, et al. The human hematopoietic stem cell compartment is heterogeneous for CXCR4 expression. Proc Natl Acad Sci U S A 2000;97:14626-31.
19. Viardot A, Kronenwett R, Deichmann M, et al. The human immunodeficiency virus (HIV)-type 1 coreceptor CXCR-4 (fusin) is preferentially expressed on the more immature CD34+ hematopoietic stem cells. Ann Hematol 1998;77:193-7.
20. Lataillade JJ, Clay D, Dupuy C, et al. Chemokine SDF-1 enahnces circulating CD34(+) cell proliferation in synergy with cytokines: possible role in progenitor survival. Blood 2000;95:756-8.
21. Lapidot T. Mechanism of human stem cell migration and repopulation of NOD/SCID and B2mnull NOD/SCID mice. Ann N Y Acad Sci 2001;938:83-95.
22. Valenzuela-Fernandez A, Planchenault T, Baleux F, et al. Leukocyte elastase negatively regulates stromal cell-derived factor-1 (SDF-1)/CXCR4 binding and functions by aminoterminal processing of SDF-1 and CXCR4. J Biol Chem 2002;277:15677-89.
23. Petit I, Szyper-Kravitz M, Nagler A, et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 2002;3:687-94.
24. Cottler-Fox MH, Lapidot T, Petit I, et al. Stem cell mobilization. Hematology (Am Soc Hematol Educ Prog) 2003:419-37.
25. Kessinger A, Sharp JG. The whys and hows of hematopoietic progenitor and stem cell mobilization. Bone Marrow Transplant 2003;31:319-29.
26. Stroncek DF, Clay ME, Petzoldt ML, et al. Treatment of normal donors with granulocyte colony-stimulating factor: donor experiences and the effects of peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells. Transfusion 1996;36:601-10.
27. Anderlini P, Korbling M, Dale D, et al. Allogeneic blood stem cell transplantation: considerations for donors. Blood 1997;90:903-8.
28. Lane TA, Ho AD, Bashey A, Peterson S, Young D, Law P. Mobilization of blood-derived stem and progenitor cells in normal subjects by granulocyte-macrophage- and granulocyte-colony-stimulating factors. Transfusion 1999;39:39-47.
29. Anderlini P, Donato M, Chan KW, et al. Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience. Transfusion 1999;39:555-60.
30. Rowley SD, Donaldson G, Lilleby K, et al. Experiences of donors enrolled in a randomized study of allogeneic bone marrow or peripheral blood stem cell transplantation. Blood 2001;97:2541-8.
31. Bensinger W, Appelbaum F, Rowley S, et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995;13:2547-55.
32. Brown RA, Adkins D, Goodnough LT, et al. Factors that influence the collection and engraftment of allogeneic peripheral-blood stem cells in patients with hematologic malignancies. J Clin Oncol 1997;15:3067-74.
33. Ford C, Chan K, Reilly W, Peterson F. An evaluation of predictive factors for CD34+ cell harvest yields from patients mobilized with chemotherapy and growth factors. Transfusion 2003;43:622-5.
34. Morris C, Siegel E, Barlogie B, et al. Mobilization of CD34+ cells in elderly patients with multiple myeloma: influence of age, prior therapy, platelet count, and mobilization regimen. Br J Haematol 2003;120:413-20.
35. Barille-Nion S, Barlogie B, Bataille R, et al. Advances in biology and therapy of multiple myeloma. Hematology (Am Soc Hematol Educ Prog) 2003:248-78.
36. Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood 2004;103:20-32.
37. Liles WC, Rodger E, Broxmeyer HE, et al. Mobilization and collection of CD34+ progenitor cells from normal human volunteers with AMD-3100, a CXCR4 antagonist, and G-CSF [abstract]. Blood 2002;100:109a.
38. Dale DC, Rodger E, Christensen J, et al. Optimizing the use of AMD3100, a CXCR4 antagonist, for mobilization of hematopoietic prgenitor cells: studies in healthy volunteers [abstract]. Blood 2003;102:38a.